JP2023531185A5 - - Google Patents

Info

Publication number
JP2023531185A5
JP2023531185A5 JP2022577477A JP2022577477A JP2023531185A5 JP 2023531185 A5 JP2023531185 A5 JP 2023531185A5 JP 2022577477 A JP2022577477 A JP 2022577477A JP 2022577477 A JP2022577477 A JP 2022577477A JP 2023531185 A5 JP2023531185 A5 JP 2023531185A5
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
nos
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531185A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037364 external-priority patent/WO2021257525A1/en
Publication of JP2023531185A publication Critical patent/JP2023531185A/ja
Publication of JP2023531185A5 publication Critical patent/JP2023531185A5/ja
Pending legal-status Critical Current

Links

JP2022577477A 2020-06-18 2021-06-15 条件的に活性な抗ネクチン4抗体 Pending JP2023531185A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063040894P 2020-06-18 2020-06-18
US63/040,894 2020-06-18
US202163166062P 2021-03-25 2021-03-25
US63/166,062 2021-03-25
PCT/US2021/037364 WO2021257525A1 (en) 2020-06-18 2021-06-15 Conditionally active anti-nectin-4 antibodies

Publications (2)

Publication Number Publication Date
JP2023531185A JP2023531185A (ja) 2023-07-21
JP2023531185A5 true JP2023531185A5 (cg-RX-API-DMAC7.html) 2024-06-18

Family

ID=79268274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577477A Pending JP2023531185A (ja) 2020-06-18 2021-06-15 条件的に活性な抗ネクチン4抗体

Country Status (11)

Country Link
US (1) US20230235054A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168453A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023531185A (cg-RX-API-DMAC7.html)
KR (1) KR20230038711A (cg-RX-API-DMAC7.html)
CN (1) CN115768798A (cg-RX-API-DMAC7.html)
AU (1) AU2021293183A1 (cg-RX-API-DMAC7.html)
CA (1) CA3182395A1 (cg-RX-API-DMAC7.html)
IL (1) IL298903A (cg-RX-API-DMAC7.html)
MX (1) MX2022016192A (cg-RX-API-DMAC7.html)
TW (2) TWI901704B (cg-RX-API-DMAC7.html)
WO (1) WO2021257525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114845740B (zh) 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
JP2024501121A (ja) * 2020-11-25 2024-01-11 イナート・ファルマ・ソシエテ・アノニム 癌の処置
KR20240026496A (ko) * 2021-06-29 2024-02-28 엘피스 바이오파마슈티컬즈 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체
CN118696061A (zh) 2022-01-12 2024-09-24 纳维再生科技股份有限公司 Nectin细胞黏附分子4之特异性抗体及其用途
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
CN117982672A (zh) * 2022-07-14 2024-05-07 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
WO2024012536A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体、其抗体药物偶联物及应用
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
KR20260085122A (ko) * 2023-09-29 2026-06-08 악티스 온콜로지, 인크. 미니단백질, 접합체 및 이의 용도
US20260226165A1 (en) * 2024-12-17 2026-08-06 Merck Sharp & Dohme Llc Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
US20110301056A1 (en) * 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
ES2874306T3 (es) * 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
EP3347048B1 (en) * 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CA3003399A1 (en) * 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
MX2019002199A (es) * 2016-08-31 2019-05-16 Bioatla Llc Polipeptidos condicionalmente activos y métodos para generarlos.
TWI870338B (zh) * 2017-06-05 2025-01-21 美商艾澤西公司 粘附分子-4結合蛋白及其使用方法
US12077583B2 (en) * 2018-05-09 2024-09-03 Nectin Therapeutics Ltd. Antibodies specific to human NECTIN4
CN112513081A (zh) * 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体

Similar Documents

Publication Publication Date Title
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
JP2022101693A5 (cg-RX-API-DMAC7.html)
Hong et al. Chemoenzymatic synthesis of a rhamnose‐functionalized bispecific nanobody as a bispecific antibody mimic for cancer immunotherapy
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
JP2021527431A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2021530987A5 (cg-RX-API-DMAC7.html)
RU2019138067A (ru) Биспецифическое антитело против ox40 и ctla-4
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2018532383A5 (cg-RX-API-DMAC7.html)
CN106659779A (zh) 双特异性四价抗体及其制造和使用方法
IL291545B1 (en) Anti-CTLA4 antibodies, antibody fragments, immunoconjugates thereof and uses thereof
JP2019512207A5 (cg-RX-API-DMAC7.html)
JP2019524640A5 (cg-RX-API-DMAC7.html)
JP2022553922A5 (cg-RX-API-DMAC7.html)
US20250034252A1 (en) Manabodies targeting p53 tumor antigens and methods of using
US12053530B2 (en) Plectin-1 binding antibodies and uses thereof
JP2024542192A5 (cg-RX-API-DMAC7.html)
JP2025513593A5 (cg-RX-API-DMAC7.html)
JP2025506248A5 (cg-RX-API-DMAC7.html)
JP2024534543A (ja) 腫瘍特異的二重特異性免疫細胞エンゲージャー
JP2023511403A5 (cg-RX-API-DMAC7.html)
JP2024508749A (ja) クローンt細胞増殖を処置するための方法および材料
JP2022513437A5 (cg-RX-API-DMAC7.html)
JP2020533002A5 (cg-RX-API-DMAC7.html)